abstract: BACKGROUND: Entities of @entity2 comprise almost inflammatory and lymphoproliferative processes as well as benign and malignant solid @entity1 and usually cannot be differentiated by magnetic resonance imaging (MRI) exclusively. Hence, representative tissue samples are needed to arrive at sufficient histopathological diagnosis for further treatment decisions. CASE REPORT: Three @entity0 aged between 18 and 67  years were admitted to our center with clinical signs of a space-occupying mass in the lacrimal fossa. MRI revealed a circumscribed lacrimal gland lesion in all three cases. The orbital lobe was resected through a lateral orbitotomy approach for histopathological evaluation. Findings confirmed the diagnoses of @entity6 , @entity5 , and low-grade B cell @entity4 . Further surgery was not necessary. No recurrence or symptoms of " @entity3 " were observed over the course of a 1-year follow-up. CONCLUSION: In cases of non-specific masses in the lacrimal gland on MRI, histopathological diagnoses are vital and can be sufficiently provided by resection of the orbital lobe. Symptoms of @entity3 are uncommon, and secondary surgical intervention can be avoided in cases of the presented entities. Further studies with larger @entity0 cohorts are warranted to confirm these findings.

title: Orbital lobe resection provides a definite diagnosis of XXXX : a report of three cases.

answer: @entity2


abstract: PURPOSE: The available literature on the treatment options for recurrent or metastatic @entity3 ( @entity3 ) is full of controversies. Therefore, we explore the results of the AGO pattern of care studies from the years 2013, 2009 and 2006. METHODS: A questionnaire was developed and sent to all 682 German gynecological departments in 2013 (775 in 2009, 500 in 2006, respectively). The results of the questionnaires were compared with each other using Fisher's exact test. RESULTS: Responses were available in 40.0  % in 2013, 33.3  % in 2009 and 35.8  % in 2006. In 2013 the most preferred endocrine drug was progestin (79.8  %), followed by @entity1 (42.8  %), aromatase inhibitor (19.8  %), @entity4 (16.3  %) and a combination (3.9  %) (p  <  0.001). 65.3, 59.8, 51.7 and 38.2  % of the @entity0 used @entity2 , @entity6 , a combination of cytostatic drugs, @entity7 in metastatic @entity3 , respectively (p  =  0.215). 96.2, 92.7, 49.8 and 60.9  % of the @entity0 performed an operation, radiotherapy, endocrine therapy and chemotherapy in 2013 because of a local recurrence, respectively (p  <  0.001). Compared to 2009 and 2006 these rates remained stable (no p value <0.05). Because of a distant metastasis 50.4, 64.2, 78.5 and 90.8  % of the @entity0 performed an operation, radiotherapy, endocrine therapy and chemotherapy in 2013, respectively (p  <  0.001). Compared to 2009 and 2006 more @entity0 performed an operation or radiotherapy and less an endocrine treatment. CONCLUSIONS: Whereas @entity5 was the favorite drug, the @entity0 of this study did not prefer a specific cytostatic drug for metastatic @entity3 in 2013. This might have reflected the available literature, which did not provide a real standard of care.

title: Management of recurrent or metastatic XXXX in Germany: results of the nationwide AGO pattern of care studies from the years 2013, 2009 and 2006.

answer: @entity3


abstract: The prefrontal cortex (PFC) elaborates and differentiates in primates, and there is a corresponding elaboration in cortical @entity2 (DA). DA cells that fire to both aversive and rewarding stimuli likely project to the dorsolateral PFC (dlPFC), signaling a salient event. Since 1979, we have known that DA has an essential influence on dlPFC working memory functions. DA has differing effects via D1 (D1R) versus @entity4 ( @entity4 ) families. D1R are concentrated on dendritic spines, and D1/5R stimulation produces an inverted U-shaped dose response on visuospatial working memory performance and Delay cell firing, the neurons that generate representations of visual space. Optimal levels of D1R stimulation gate out "noise," whereas higher levels, e.g., during stress, suppress Delay cell firing. These effects likely involve hyperpolarization-activated @entity6 -gated channel opening, activation of @entity3 interneurons, and reduced @entity5 release. Dysregulation of D1R has been related to @entity0 in @entity1 , and there is a need for new, lower-affinity D1R agonists that may better mimic endogenous DA to enhance mental representations and improve cognition. In contrast to D1R, @entity4 are primarily localized on layer V pyramidal cell dendrites, and D2/3R stimulation speeds and magnifies the firing of Response cells, including Response Feedback cells. Altered firing of Feedback neurons may relate to positive symptoms in @entity1 . Emerging research suggests that DA may have similar effects in the ventrolateral PFC and frontal eye fields. Research on the orbital PFC in monkeys is just beginning and could be a key area for future discoveries.

title: XXXX 's Actions in Primate Prefrontal Cortex: Challenges for Treating @entity0 .

answer: @entity2


abstract: The prefrontal cortex (PFC) elaborates and differentiates in primates, and there is a corresponding elaboration in cortical @entity2 (DA). DA cells that fire to both aversive and rewarding stimuli likely project to the dorsolateral PFC (dlPFC), signaling a salient event. Since 1979, we have known that DA has an essential influence on dlPFC working memory functions. DA has differing effects via D1 (D1R) versus @entity4 ( @entity4 ) families. D1R are concentrated on dendritic spines, and D1/5R stimulation produces an inverted U-shaped dose response on visuospatial working memory performance and Delay cell firing, the neurons that generate representations of visual space. Optimal levels of D1R stimulation gate out "noise," whereas higher levels, e.g., during stress, suppress Delay cell firing. These effects likely involve hyperpolarization-activated @entity6 -gated channel opening, activation of @entity3 interneurons, and reduced @entity5 release. Dysregulation of D1R has been related to @entity0 in @entity1 , and there is a need for new, lower-affinity D1R agonists that may better mimic endogenous DA to enhance mental representations and improve cognition. In contrast to D1R, @entity4 are primarily localized on layer V pyramidal cell dendrites, and D2/3R stimulation speeds and magnifies the firing of Response cells, including Response Feedback cells. Altered firing of Feedback neurons may relate to positive symptoms in @entity1 . Emerging research suggests that DA may have similar effects in the ventrolateral PFC and frontal eye fields. Research on the orbital PFC in monkeys is just beginning and could be a key area for future discoveries.

title: @entity2 's Actions in Primate Prefrontal Cortex: Challenges for Treating XXXX .

answer: @entity0


abstract: OBJECTIVE: Coexistence of @entity8 ( @entity8 ) and @entity6 is a rare condition that is rarely described in the literature. The aim of the study was to describe the main characteristics of @entity0 presenting with both @entity6 and @entity8 . METHODS: A retrospective study of @entity8 @entity0 in the @entity4 Study Group cohort who also had a diagnosis of @entity6 was conducted. We reviewed the medical records and outcomes of these @entity0 . RESULTS: We identified 11 @entity0 with @entity8 and @entity6 . Four @entity0 with eosinophilic @entity5 with @entity5 ( @entity7 ) also had @entity2 and seven @entity0 with @entity5 with @entity5 (GPA) had @entity1 . No @entity1 was observed in eosinophilic GPA and no @entity2 in GPA. @entity6 started before @entity8 manifestations in six cases, simultaneously in two cases and after @entity8 manifestations in three cases. CONCLUSION: Coexistence of @entity6 and @entity8 is a rare condition. The therapeutic management of these @entity0 includes corticosteroids in all cases and immunosuppressive drugs in some @entity0 . Coexistence of @entity6 and @entity8 might be explained by common underlying inflammatory responses and cytokine profiles polarized towards either @entity3 or Th2. Finally, in the presence of digestive manifestations in the context of @entity8 , the hypothesis of @entity6 should be assessed.

title: Inflammatory bowel diseases in anti-neutrophil cytoplasmic antibody-associated vasculitides: 11 retrospective cases from the XXXX Study Group.

answer: @entity4


abstract: Following elective total hip replacement, both continuous lumbar plexus blockade and spinal anaesthesia (with adjunctive intrathecal @entity6 ) have shown early outcome benefits over opioid @entity7 and single-injection nerve block. However, the two techniques have not been compared in a prospective randomised manner. Our study examined 50 @entity0 undergoing elective hip joint replacement who were randomised to receive spinal anaesthesia (with adjunctive intrathecal @entity6 0.1 mg) or @entity0 -controlled continuous lumbar plexus blockade. All surgery was conducted under general anaesthesia. Measured outcomes included numerically rated @entity5 , @entity8 and indices of mobilisation together with complications. Results show that block placement time was marginally shorter for the spinal group (5 versus 7 minutes, P=0.01). The primary outcome, @entity4 on movement/mobilisation during the first 24 hours, was not statistically significantly different between groups. @entity0 in the lumbar plexus group were given more intraoperative opioid and rescue @entity6 in the post-anaesthesia care unit (median = 4 versus 0 mg, P <0.001), with correspondingly higher @entity4 scores (median 5/10 versus 0/10, P <0.001). @entity4 scores during the subsequent 24 hours were similar between groups, but more @entity0 in the spinal group were given rescue @entity6 (5 versus 0, P=0.02). Physiotherapy mobilisation indices appeared similar between groups. More spinal group @entity0 reported @entity3 (12 versus 5, P=0.01), but antiemetic requirements, episodes of disorientation, arterial @entity2 desaturation and falls were all similar between groups. Postoperative symptoms suggestive of @entity1 or injury did not differ between groups. We found that following elective hip joint replacement, compared to continuous lumbar plexus blockade, spinal anaesthesia incorporating adjunctive intrathecal @entity6 did not result in a statistically significant difference in @entity4 on movement/mobilisation during the first 24 hours, although it was associated with better @entity7 in the post-anaesthesia care unit. Subsequently, however, these @entity0 appeared to require more rescue @entity6 and more of them reported @entity3 .

title: Spinal anaesthesia with adjunctive intrathecal @entity6 versus continuous lumbar plexus blockade: a randomised comparison for XXXX after hip replacement.

answer: @entity7


abstract: Following elective total hip replacement, both continuous lumbar plexus blockade and spinal anaesthesia (with adjunctive intrathecal @entity6 ) have shown early outcome benefits over opioid @entity7 and single-injection nerve block. However, the two techniques have not been compared in a prospective randomised manner. Our study examined 50 @entity0 undergoing elective hip joint replacement who were randomised to receive spinal anaesthesia (with adjunctive intrathecal @entity6 0.1 mg) or @entity0 -controlled continuous lumbar plexus blockade. All surgery was conducted under general anaesthesia. Measured outcomes included numerically rated @entity5 , @entity8 and indices of mobilisation together with complications. Results show that block placement time was marginally shorter for the spinal group (5 versus 7 minutes, P=0.01). The primary outcome, @entity4 on movement/mobilisation during the first 24 hours, was not statistically significantly different between groups. @entity0 in the lumbar plexus group were given more intraoperative opioid and rescue @entity6 in the post-anaesthesia care unit (median = 4 versus 0 mg, P <0.001), with correspondingly higher @entity4 scores (median 5/10 versus 0/10, P <0.001). @entity4 scores during the subsequent 24 hours were similar between groups, but more @entity0 in the spinal group were given rescue @entity6 (5 versus 0, P=0.02). Physiotherapy mobilisation indices appeared similar between groups. More spinal group @entity0 reported @entity3 (12 versus 5, P=0.01), but antiemetic requirements, episodes of disorientation, arterial @entity2 desaturation and falls were all similar between groups. Postoperative symptoms suggestive of @entity1 or injury did not differ between groups. We found that following elective hip joint replacement, compared to continuous lumbar plexus blockade, spinal anaesthesia incorporating adjunctive intrathecal @entity6 did not result in a statistically significant difference in @entity4 on movement/mobilisation during the first 24 hours, although it was associated with better @entity7 in the post-anaesthesia care unit. Subsequently, however, these @entity0 appeared to require more rescue @entity6 and more of them reported @entity3 .

title: Spinal anaesthesia with adjunctive intrathecal XXXX versus continuous lumbar plexus blockade: a randomised comparison for @entity7 after hip replacement.

answer: @entity6


abstract: UNASSIGNED: Stress has been shown to affect the immune system of @entity0 making them more susceptible to @entity3 . Five-week-old male and female @entity0 were treated with 3 intra-muscular injections of @entity2 ( @entity4 ) at 0, 0.5 and 2.0mg/kg body weight. Twenty-four hours after the third injection birds were bled and white blood cell (WBC) differentials and bacteriostatic activity of monocytes were measured. @entity4 at both 0.5 and 2.0mg/kg decreased phagocytic activity in females only. Bacteriostatic activity was decreased at both concentrations of @entity4 at 8 and 16h post-infection in both sexes and was lower in males as compared to females. Total WBC counts were increased in females at both concentrations of @entity4 whereas male total WBC counts were unaffected. Both males and females had an increase in the heterophil to lymphocyte ratio. Within the same study, replicate pens of @entity0 were challenged with intra-air sac inoculation of 100cfu of @entity1 . Isolation of @entity1 was significantly increased by both @entity4 and @entity1 challenge, but there were no differences between sexes. These results suggest that stress can compromise the bacteriostatic activity of @entity0 monocytes and increase bacterial colonization of blood and tissues, potentially affecting food safety.

title: Effect of @entity2 on bacteriostatic activity of XXXX monocytes and implications for food safety.

answer: @entity0


abstract: UNASSIGNED: Stress has been shown to affect the immune system of @entity0 making them more susceptible to @entity3 . Five-week-old male and female @entity0 were treated with 3 intra-muscular injections of @entity2 ( @entity4 ) at 0, 0.5 and 2.0mg/kg body weight. Twenty-four hours after the third injection birds were bled and white blood cell (WBC) differentials and bacteriostatic activity of monocytes were measured. @entity4 at both 0.5 and 2.0mg/kg decreased phagocytic activity in females only. Bacteriostatic activity was decreased at both concentrations of @entity4 at 8 and 16h post-infection in both sexes and was lower in males as compared to females. Total WBC counts were increased in females at both concentrations of @entity4 whereas male total WBC counts were unaffected. Both males and females had an increase in the heterophil to lymphocyte ratio. Within the same study, replicate pens of @entity0 were challenged with intra-air sac inoculation of 100cfu of @entity1 . Isolation of @entity1 was significantly increased by both @entity4 and @entity1 challenge, but there were no differences between sexes. These results suggest that stress can compromise the bacteriostatic activity of @entity0 monocytes and increase bacterial colonization of blood and tissues, potentially affecting food safety.

title: Effect of XXXX on bacteriostatic activity of @entity0 monocytes and implications for food safety.

answer: @entity2


abstract: AIMS: Due to the paucity of studies focusing on primary @entity6 , the second commonest cause of @entity4 in most of the developed world, we sought to review outcomes of these renal pathologies. METHODS: We reviewed outcomes of primary @entity6 in @entity0 enrolled in the New Zealand @entity6 Study between 1972 and 1983 focusing on renal outcomes and mortality. RESULTS: There were 765 @entity0 with a median follow-up of 30 years (range 0  1- 42years). They were predominantly New Zealand European, male and @entity2 . Poor renal outcomes and increased mortality were associated with @entity2 , @entity7 greater than 1g/day, reduced estimated glomerular filtration rate and older age at diagnosis. Ethnicity was not significantly associated with progression to @entity4 although indigenous NZ Maori @entity0 were at significantly increased risk of @entity3 . @entity0 diagnosed with rapidly progressive @entity6 were 5 times more likely than those with minimal change @entity1 to reach @entity4 . The cumulative incidence of @entity4 was approximately 20% for those with immunoglobulin-A @entity1 , and 30% @entity1 @entity0 . @entity0 with rapidly progressive @entity6 and @entity1 were at increased risk of @entity3 , although the latter were not at increased risk of @entity4 if they survived. The era of diagnosis did not have much effect on outcomes except for @entity0 diagnosed with @entity5 or immunoglobulin A @entity1 but this could be type II error. CONCLUSION: We report one of the longest follow-up studies on biopsy-proven @entity6 . Age, @entity2 , and severity of @entity8 at diagnosis were strong predictors of the development of @entity4 and @entity3 . The specific renal pathology had a profound impact upon prognosis and therefore should continue to drive efforts to find targeted therapeutic options for these @entity6 .

title: Long-term outcomes for primary @entity6 : New Zealand XXXX study.

answer: @entity6


abstract: AIMS: Due to the paucity of studies focusing on primary @entity6 , the second commonest cause of @entity4 in most of the developed world, we sought to review outcomes of these renal pathologies. METHODS: We reviewed outcomes of primary @entity6 in @entity0 enrolled in the New Zealand @entity6 Study between 1972 and 1983 focusing on renal outcomes and mortality. RESULTS: There were 765 @entity0 with a median follow-up of 30 years (range 0  1- 42years). They were predominantly New Zealand European, male and @entity2 . Poor renal outcomes and increased mortality were associated with @entity2 , @entity7 greater than 1g/day, reduced estimated glomerular filtration rate and older age at diagnosis. Ethnicity was not significantly associated with progression to @entity4 although indigenous NZ Maori @entity0 were at significantly increased risk of @entity3 . @entity0 diagnosed with rapidly progressive @entity6 were 5 times more likely than those with minimal change @entity1 to reach @entity4 . The cumulative incidence of @entity4 was approximately 20% for those with immunoglobulin-A @entity1 , and 30% @entity1 @entity0 . @entity0 with rapidly progressive @entity6 and @entity1 were at increased risk of @entity3 , although the latter were not at increased risk of @entity4 if they survived. The era of diagnosis did not have much effect on outcomes except for @entity0 diagnosed with @entity5 or immunoglobulin A @entity1 but this could be type II error. CONCLUSION: We report one of the longest follow-up studies on biopsy-proven @entity6 . Age, @entity2 , and severity of @entity8 at diagnosis were strong predictors of the development of @entity4 and @entity3 . The specific renal pathology had a profound impact upon prognosis and therefore should continue to drive efforts to find targeted therapeutic options for these @entity6 .

title: Long-term outcomes for primary XXXX : New Zealand @entity6 study.

answer: @entity6


abstract: IMPORTANCE: @entity2 ( @entity2 ) are not recommended within 40 days of @entity1 ( @entity1 ); thus, @entity4 implantation might not be considered during the post- @entity1 care transition. OBJECTIVE: To examine @entity4 implantation rates and associated mortality among older @entity1 @entity0 with low ejection fraction (EF). DESIGN, SETTING, AND @entity0 : Retrospective observational study of Medicare beneficiaries with an EF of 35% or less after @entity1 , treated at 441 US hospitals between 2007 and 2010, excluding @entity0 with prior @entity4 implantation. Follow-up data were available through December 2010. EXPOSURES: @entity4 implantation within 1 year of @entity1 vs no @entity4 implantation within 1 year of @entity1 . MAIN OUTCOMES AND MEASURES: @entity0 characteristics associated with receiving an @entity4 within 1 year after discharge and 2-year mortality associated with @entity4 implantation. RESULTS: Among 10,318 @entity1 @entity0 with EF of 35%or lower, the cumulative 1-year @entity4 implantation rate was 8.1% (95%CI, 7.6%-8.7%). @entity0 with @entity4 implantation were more likely to have prior coronary artery bypass graft procedures, higher peak troponin levels, in-hospital @entity3 , and cardiology follow-up within 2 weeks after discharge relative to @entity0 who did not receive an @entity4 within 1 year. Implantation of @entity4 was associated with lower 2-year mortality (15.3 events per 100 @entity0 -years [128 deaths in 838 @entity0 -years] vs 26.4 events per 100 @entity0 -years [3033 deaths in 11 479 @entity0 -years]; adjusted HR, 0.64; 95%CI, 0.53-0.78). [table: see text] CONCLUSIONS AND RELEVANCE: In this large registry study of older @entity0 who experienced @entity1 from 2007-2010, fewer than 1 in 10 eligible @entity0 with low EF received an @entity4 within 1 year after @entity1 , although @entity4 implantation was associated with lower risk-adjusted mortality at 2 years. Additional research is needed to determine evidence-based approaches to increase @entity4 implantation among eligible @entity0 .

title: Implantable Cardioverter-Defibrillator Use Among Medicare @entity0 With Low Ejection Fraction After Acute XXXX .

answer: @entity1


abstract: IMPORTANCE: @entity2 ( @entity2 ) are not recommended within 40 days of @entity1 ( @entity1 ); thus, @entity4 implantation might not be considered during the post- @entity1 care transition. OBJECTIVE: To examine @entity4 implantation rates and associated mortality among older @entity1 @entity0 with low ejection fraction (EF). DESIGN, SETTING, AND @entity0 : Retrospective observational study of Medicare beneficiaries with an EF of 35% or less after @entity1 , treated at 441 US hospitals between 2007 and 2010, excluding @entity0 with prior @entity4 implantation. Follow-up data were available through December 2010. EXPOSURES: @entity4 implantation within 1 year of @entity1 vs no @entity4 implantation within 1 year of @entity1 . MAIN OUTCOMES AND MEASURES: @entity0 characteristics associated with receiving an @entity4 within 1 year after discharge and 2-year mortality associated with @entity4 implantation. RESULTS: Among 10,318 @entity1 @entity0 with EF of 35%or lower, the cumulative 1-year @entity4 implantation rate was 8.1% (95%CI, 7.6%-8.7%). @entity0 with @entity4 implantation were more likely to have prior coronary artery bypass graft procedures, higher peak troponin levels, in-hospital @entity3 , and cardiology follow-up within 2 weeks after discharge relative to @entity0 who did not receive an @entity4 within 1 year. Implantation of @entity4 was associated with lower 2-year mortality (15.3 events per 100 @entity0 -years [128 deaths in 838 @entity0 -years] vs 26.4 events per 100 @entity0 -years [3033 deaths in 11 479 @entity0 -years]; adjusted HR, 0.64; 95%CI, 0.53-0.78). [table: see text] CONCLUSIONS AND RELEVANCE: In this large registry study of older @entity0 who experienced @entity1 from 2007-2010, fewer than 1 in 10 eligible @entity0 with low EF received an @entity4 within 1 year after @entity1 , although @entity4 implantation was associated with lower risk-adjusted mortality at 2 years. Additional research is needed to determine evidence-based approaches to increase @entity4 implantation among eligible @entity0 .

title: Implantable Cardioverter-Defibrillator Use Among Medicare XXXX With Low Ejection Fraction After Acute @entity1 .

answer: @entity0


abstract: BACKGROUND: @entity3 mediates the transcription of a large number of constitutive genes encoding physiological mediators. NF-kB mediates the expression of hundreds of inducible genes encoding pathological mediators. Crosstalk between @entity3 and NF-kB pathways could be pathophysiologically significant, but has not been studied. This study examined the crosstalk between the two pathways and defined the role of NF-kB signaling in @entity1 -induced down-regulation of @entity3 activity. METHODS AND MAIN FINDINGS: Challenge of wild type @entity0 with samonelia enteritidis @entity1 (10 mg/kg, i.p.) down-regulated @entity3 binding activity in lungs in a time-dependent manner, which was concomitantly associated with an increased NF-kB activity. @entity1 down-regulates @entity3 activity by inducing an @entity1 inducible @entity3 -degrading enzyme (LISPDE) activity, which selectively degrades @entity3 protein, resulting in @entity3 down-regulation. Blockade of NF-kB activation in @entity0 deficient in NF-kB p50 gene (NF-kB-KO) suppressed LISPDE activity, prevented @entity3 protein degradation, and reversed the down-regulation of @entity3 DNA binding activity and eNOS expression (an indicator of @entity3 transactivation activity). Inhibition of LISPDE activity using a selective LISPDE inhibitor mimicked the effects of NF-kB blockade. Pretreatment of @entity1 -challenged WT @entity0 with a selective LISPDE inhibitor increased nuclear @entity3 protein content, restored @entity3 DNA binding activity and reversed eNOS protein down-regulation in lungs. Enhancing tissue level of @entity3 activity by inhibiting NF-kB-mediated @entity3 down-regulation increased tissue level of @entity2 and decreased tissue level of TNF- ain the lungs. CONCLUSIONS: NF-kB signaling mediates @entity1 -induced down-regulation of @entity3 activity. Activation of NF-kB pathway suppresses @entity3 activity and @entity3 -mediated anti-inflammatory signals. Conversely, @entity3 signaling counter-regulates NF-kB-mediated inflammatory response. Crosstalk between NF-kB and @entity3 pathways regulates the balance between pro- and anti-inflammatory cytokines.

title: XXXX Down-Regulates Specificity Protein 1 Activity by Activating NF-kB Pathway in Endotoxemic @entity0 .

answer: @entity1


abstract: BACKGROUND: @entity3 mediates the transcription of a large number of constitutive genes encoding physiological mediators. NF-kB mediates the expression of hundreds of inducible genes encoding pathological mediators. Crosstalk between @entity3 and NF-kB pathways could be pathophysiologically significant, but has not been studied. This study examined the crosstalk between the two pathways and defined the role of NF-kB signaling in @entity1 -induced down-regulation of @entity3 activity. METHODS AND MAIN FINDINGS: Challenge of wild type @entity0 with samonelia enteritidis @entity1 (10 mg/kg, i.p.) down-regulated @entity3 binding activity in lungs in a time-dependent manner, which was concomitantly associated with an increased NF-kB activity. @entity1 down-regulates @entity3 activity by inducing an @entity1 inducible @entity3 -degrading enzyme (LISPDE) activity, which selectively degrades @entity3 protein, resulting in @entity3 down-regulation. Blockade of NF-kB activation in @entity0 deficient in NF-kB p50 gene (NF-kB-KO) suppressed LISPDE activity, prevented @entity3 protein degradation, and reversed the down-regulation of @entity3 DNA binding activity and eNOS expression (an indicator of @entity3 transactivation activity). Inhibition of LISPDE activity using a selective LISPDE inhibitor mimicked the effects of NF-kB blockade. Pretreatment of @entity1 -challenged WT @entity0 with a selective LISPDE inhibitor increased nuclear @entity3 protein content, restored @entity3 DNA binding activity and reversed eNOS protein down-regulation in lungs. Enhancing tissue level of @entity3 activity by inhibiting NF-kB-mediated @entity3 down-regulation increased tissue level of @entity2 and decreased tissue level of TNF- ain the lungs. CONCLUSIONS: NF-kB signaling mediates @entity1 -induced down-regulation of @entity3 activity. Activation of NF-kB pathway suppresses @entity3 activity and @entity3 -mediated anti-inflammatory signals. Conversely, @entity3 signaling counter-regulates NF-kB-mediated inflammatory response. Crosstalk between NF-kB and @entity3 pathways regulates the balance between pro- and anti-inflammatory cytokines.

title: @entity1 Down-Regulates Specificity Protein 1 Activity by Activating NF-kB Pathway in Endotoxemic XXXX .

answer: @entity0


abstract: UNASSIGNED: In order to locate @entity0 on kV projection images without internal markers, digitally reconstructed radiographs (DRRs) are created and compared with projection images. However, @entity0 always move due to respiration and their locations change on projection images while they are static on DRRs. In addition, global image intensity discrepancies exist between DRRs and projections due to their different image orientations, scattering, and noises. This adversely affects comparison accuracy. A simple but efficient comparison algorithm is reported to match imperfectly matched projection images and DRRs. The kV projection images were matched with different DRRs in two steps. Preprocessing was performed in advance to generate two sets of DRRs. The @entity1 were removed from the planning 3D CT for a single phase of planning 4D CT images using planning contours of @entity1 . DRRs of background and DRRs of @entity1 were generated separately for every projection angle. The first step was to match projection images with DRRs of background signals. This method divided global images into a matrix of small tiles and similarities were evaluated by calculating normalized cross-correlation (NCC) between corresponding tiles on projections and DRRs. The tile configuration (tile locations) was automatically optimized to keep the @entity1 within a single projection tile that had a bad matching with the corresponding DRR tile. A pixel-based linear transformation was determined by linear interpolations of tile transformation results obtained during tile matching. The background DRRs were transformed to the projection image level and subtracted from it. The resulting subtracted image now contained only the @entity1 . The second step was to register DRRs of @entity1 to the subtracted image to locate the @entity1 . This method was successfully applied to kV fluoro images (about 1000 images) acquired on a Vero (BrainLAB) for @entity1 tracking on phantom studies. Radiation opaque markers were implanted and used as ground truth for @entity1 positions. Although other organs and bony structures introduced strong signals superimposed on @entity1 at some angles, this method accurately located @entity1 on every projection over 12 gantry angles. The maximum error was less than 2.2 mm, while the total average error was less than 0.9mm. This algorithm was capable of detecting @entity1 without markers, despite strong background signals.

title: An accurate algorithm to match imperfectly matched images for XXXX detection without markers.

answer: @entity0


abstract: OBJECTIVE: @entity3 ( @entity3 ) is characterized by severe and often progressive @entity2 of the skin and multiple internal organs. The mechanisms responsible for these alterations remain obscure, although excessive reactive @entity1 species (ROS)-mediated oxidative stress has been implicated. @entity9 is 1 of 7 isoforms of @entity4 oxidase responsible for the generation of ROS. The purpose of this study was to examine @entity9 expression in skin and cultured dermal fibroblasts from @entity3 @entity0 and to examine its regulation by @entity5 ( @entity5 ). METHODS: @entity9 was assessed in normal and @entity3 skin by immunohistologic analysis and in normal and @entity3 cultured dermal fibroblasts by quantitative polymerase chain reaction analysis, fluorescence microscopy, and Western blotting. ROS levels were assessed by fluorescence measurement of @entity6 production. Specific kinase inhibitors were used to study the @entity5 signaling involved in @entity9 stimulation. @entity9 inhibition/down-regulation was induced with a selective @entity9 small-molecule inhibitor and @entity9 small interfering RNA (siRNA). RESULTS: In contrast with normal skin fibroblasts, those from @entity3 skin showed intense @entity9 staining. Cultured @entity3 fibroblasts displayed increased @entity9 expression. @entity5 caused potent @entity9 protein and messenger RNA stimulation in normal and @entity3 fibroblasts, which was mediated by the @entity7   ( @entity7  ) and @entity8 pathways. @entity9 knockdown in @entity3 fibroblasts reduced the production of ROS and lowered the expression of type I collagen. CONCLUSION: @entity9 expression and production were found to be constitutively elevated in @entity3 skin and cultured @entity3 dermal fibroblasts. @entity5 stimulated @entity9 expression in normal and @entity3 fibroblasts through @entity7   and @entity8 signaling pathways. A small-molecule @entity9 inhibitor decreased collagen and fibronectin production by normal and @entity3 fibroblasts, and @entity9 siRNA knockdown reduced ROS and collagen production by @entity3 fibroblasts. These results demonstrate the involvement of @entity9 in @entity3 -associated @entity2 and indicate @entity9 inhibitors as novel therapeutic approaches for @entity3 .

title: Increased expression of NAPDH oxidase 4 in XXXX dermal fibroblasts: regulation by transforming growth factor b.

answer: @entity3


abstract: This experiment was conducted to identify some aspects of secondary follicle (SF) characteristics of Hexi cashmere @entity2 at five different growing stages in one year in order and discover the expression pattern of @entity4 in a SF cycling to provide morphological basis for studying the growth of cashmere. Ten cashmere @entity2 of one-year old (5 males, 5 females) were included in this study. The density and activity of SF were observed and measured by making paraffin sections, the ultra-structural features of SF were studied under transmission electron microscopy (TEM) by making ultra-thin sections, and the expression of @entity4 was investigated through the immunohistochemistry method. The average diameter of SF had the smallest value in the anagen stage, and significant difference (P   <   0.05) was found between the anagen stage and other stages. The density of SF increased gradually through the different growing stages, and significant difference was found between the anagen and procatagen stages (P   <   0.05). With an increase in time (months), the percentage of SF activity increased, and significant difference in the percentage of SF activity was found between the telogen and anagen stages (P   <   0.05). At the telogen stage, the layers of @entity3 ( @entity3 ) of SF were unclear, hemidesmosomes between the outer root sheath (ORS) and basement membrane disappeared, and dead cells were found at the top of the SF. The rudiments of new SF were found in the proanagen stage, @entity3 was thickened, and the cells of ORS were stretched out like fingers. At the anagen stage, the structure of SF was integral, and the @entity0 ( @entity0 ) consisted of three concentric layers (Helen, Huxley, and @entity1 ). The cells of Huxley's layer degenerated gradually, and pseudopodia were formed on the cells of ORS in the procatagen stage. At the catagen stage, the ORS was separated from the @entity0 , and @entity0 disappeared. Huxley's layer was absent in the inactive SF while, the ORS was present in the active SF. @entity4 was expressed in the epidermis and sebaceous gland o, ORS, @entity0 , hair shaft of SF in the skin. @entity4 was expressed weakly during procatagen, catagen, and telogen stage, while with an increase in proanagen and anagen stage, significant difference was found between them. These findings demonstrated the ultra-structural features of SF could provide the useful activity criteria, and @entity4 associated with the SF activity.

title: Determination of Secondary Follicle Characteristics, Density, Activity, and XXXX Expression Pattern of Hexi Cashmere @entity2 Breed.

answer: @entity4


abstract: This experiment was conducted to identify some aspects of secondary follicle (SF) characteristics of Hexi cashmere @entity2 at five different growing stages in one year in order and discover the expression pattern of @entity4 in a SF cycling to provide morphological basis for studying the growth of cashmere. Ten cashmere @entity2 of one-year old (5 males, 5 females) were included in this study. The density and activity of SF were observed and measured by making paraffin sections, the ultra-structural features of SF were studied under transmission electron microscopy (TEM) by making ultra-thin sections, and the expression of @entity4 was investigated through the immunohistochemistry method. The average diameter of SF had the smallest value in the anagen stage, and significant difference (P   <   0.05) was found between the anagen stage and other stages. The density of SF increased gradually through the different growing stages, and significant difference was found between the anagen and procatagen stages (P   <   0.05). With an increase in time (months), the percentage of SF activity increased, and significant difference in the percentage of SF activity was found between the telogen and anagen stages (P   <   0.05). At the telogen stage, the layers of @entity3 ( @entity3 ) of SF were unclear, hemidesmosomes between the outer root sheath (ORS) and basement membrane disappeared, and dead cells were found at the top of the SF. The rudiments of new SF were found in the proanagen stage, @entity3 was thickened, and the cells of ORS were stretched out like fingers. At the anagen stage, the structure of SF was integral, and the @entity0 ( @entity0 ) consisted of three concentric layers (Helen, Huxley, and @entity1 ). The cells of Huxley's layer degenerated gradually, and pseudopodia were formed on the cells of ORS in the procatagen stage. At the catagen stage, the ORS was separated from the @entity0 , and @entity0 disappeared. Huxley's layer was absent in the inactive SF while, the ORS was present in the active SF. @entity4 was expressed in the epidermis and sebaceous gland o, ORS, @entity0 , hair shaft of SF in the skin. @entity4 was expressed weakly during procatagen, catagen, and telogen stage, while with an increase in proanagen and anagen stage, significant difference was found between them. These findings demonstrated the ultra-structural features of SF could provide the useful activity criteria, and @entity4 associated with the SF activity.

title: Determination of Secondary Follicle Characteristics, Density, Activity, and @entity4 Expression Pattern of Hexi Cashmere XXXX Breed.

answer: @entity2


abstract: Between 1979 and 1985, 552 Ionescu-Shiley valves were implanted in 511 @entity0 . The Hancock valve was implanted in 122 @entity0 (129 valves) between 1982 and 1983. Sixty percent of procedures were isolated aortic valve replacements. In the Ionescu series, 59% of these were 19 or 21 mm valves while only 15% of the Hancock valves were of this size. For isolated mitral valve replacement, 76% of Ionescu-Shiley valves were 25 to 27 mm, compared to 36% of the Hancock valves. @entity0 age, sex, prior operations, concomitant surgery (usually coronary bypass), operative mortality and late deaths were similar for both valves. A mean follow-up of 38 months was obtained for each valve population (99% complete) representing a cumulative 1497 @entity0 -years for the Ionescu-Shiley valve and 375.4 @entity0 -years for the Hancock valve. Actuarial survival for the former was 73 +/- 4% at 72 months, and 65 +/- 14% for Hancock valves at 60 months. The frequency of major events during follow-up ( @entity3 , anticoagulant related @entity2 , bland @entity4 and @entity1 ) were similar, but the frequency of primary tissue valve failure was markedly different for the two valves (1.1% per @entity0 -year for Ionescu-Shiley valves and 5.9% for the Hancock valve). The mean interval to replacement of an Ionescu mitral prosthesis was significantly shorter (23.4 months) than for replacement of an aortic prosthesis (42 months) while the mean interval to replacement of an Ionescu aortic and/or a Hancock aortic or mitral were all similar.(ABSTRACT TRUNCATED AT 250 WORDS)

title: Clinical results of pericardial xenograft valves: the XXXX .

answer: @entity1


abstract: @entity10 is a dechlorinated derivative of @entity11 which preclinically synergizes with @entity4 . Clinically, this nonmyelosuppressive drug (given p.o. daily) is active as a single agent in a variety of @entity2 . On this basis, a Phase I study which incorporates a drug escalation schema as well as an escalation in temperature, i.e., 41.0 degrees C for 85 min to 41.8 degrees C for 75 min, was executed. Induction therapy included seven whole-body @entity4 treatments. Whole-body @entity4 was delivered using a radiant heat system. Twenty-four @entity0 were entered on study. Of these, 20 were evaluable for response. Group A (60 mg/m2) had three @entity0 with three no responses. Group B (180 mg/m2) consisted of three @entity0 : one @entity8 , partial response; two @entity6 , one partial response and one improvement, i.e., less than a partial response. Group C (360 mg/m2) had 17 @entity0 : two @entity1 , one complete response and one improvement; one @entity5 , improvement; one ovarian, disease stabilization (greater than 100 days); two @entity7 of the gastrointestinal tract, two disease stabilizations; 11 @entity0 , no responses; one @entity0 entered at this level was ineligible for study and did not receive @entity10 . Therapy was well tolerated. Of 16 @entity0 reporting @entity9 , two required a @entity10 dose reduction; one @entity0 required dose reduction for @entity3 . Results obtained encourage Phase II clinical trials.

title: Phase I trial of @entity10 with whole body XXXX in @entity2 .

answer: @entity4


abstract: @entity10 is a dechlorinated derivative of @entity11 which preclinically synergizes with @entity4 . Clinically, this nonmyelosuppressive drug (given p.o. daily) is active as a single agent in a variety of @entity2 . On this basis, a Phase I study which incorporates a drug escalation schema as well as an escalation in temperature, i.e., 41.0 degrees C for 85 min to 41.8 degrees C for 75 min, was executed. Induction therapy included seven whole-body @entity4 treatments. Whole-body @entity4 was delivered using a radiant heat system. Twenty-four @entity0 were entered on study. Of these, 20 were evaluable for response. Group A (60 mg/m2) had three @entity0 with three no responses. Group B (180 mg/m2) consisted of three @entity0 : one @entity8 , partial response; two @entity6 , one partial response and one improvement, i.e., less than a partial response. Group C (360 mg/m2) had 17 @entity0 : two @entity1 , one complete response and one improvement; one @entity5 , improvement; one ovarian, disease stabilization (greater than 100 days); two @entity7 of the gastrointestinal tract, two disease stabilizations; 11 @entity0 , no responses; one @entity0 entered at this level was ineligible for study and did not receive @entity10 . Therapy was well tolerated. Of 16 @entity0 reporting @entity9 , two required a @entity10 dose reduction; one @entity0 required dose reduction for @entity3 . Results obtained encourage Phase II clinical trials.

title: Phase I trial of XXXX with whole body @entity4 in @entity2 .

answer: @entity10


abstract: @entity10 is a dechlorinated derivative of @entity11 which preclinically synergizes with @entity4 . Clinically, this nonmyelosuppressive drug (given p.o. daily) is active as a single agent in a variety of @entity2 . On this basis, a Phase I study which incorporates a drug escalation schema as well as an escalation in temperature, i.e., 41.0 degrees C for 85 min to 41.8 degrees C for 75 min, was executed. Induction therapy included seven whole-body @entity4 treatments. Whole-body @entity4 was delivered using a radiant heat system. Twenty-four @entity0 were entered on study. Of these, 20 were evaluable for response. Group A (60 mg/m2) had three @entity0 with three no responses. Group B (180 mg/m2) consisted of three @entity0 : one @entity8 , partial response; two @entity6 , one partial response and one improvement, i.e., less than a partial response. Group C (360 mg/m2) had 17 @entity0 : two @entity1 , one complete response and one improvement; one @entity5 , improvement; one ovarian, disease stabilization (greater than 100 days); two @entity7 of the gastrointestinal tract, two disease stabilizations; 11 @entity0 , no responses; one @entity0 entered at this level was ineligible for study and did not receive @entity10 . Therapy was well tolerated. Of 16 @entity0 reporting @entity9 , two required a @entity10 dose reduction; one @entity0 required dose reduction for @entity3 . Results obtained encourage Phase II clinical trials.

title: Phase I trial of @entity10 with whole body @entity4 in XXXX .

answer: @entity2


abstract: Experiments were performed on @entity0 superfused ventricular epicardial tissue slices to determine the effects of 1.0-2.0 mM @entity1 , an uncoupling agent, on conduction longitudinal and transverse to myocardial fiber orientation. Conduction velocities were measured between proximal and distal pairs of epicardial electrodes oriented transverse and longitudinal to the direction of a conducted wavefront evoked by pacing at a basic cycle length of 2,000 msec from one margin of the tissue before and after the addition of @entity1 . In a separate group of tissues, the dual bipolar orthogonal electrode was used to sequentially map epicardial activation at 40 to 45 sites in a 1 cm x 2 cm area before and 30 minutes after the introduction of @entity1 . In a third group of tissues, transmembrane potentials were recorded with standard microelectrode techniques to determine the effects of @entity1 on action potential characteristics. @entity1 did not significantly effect action potential amplitude or maximum rate of depolarization. After 1.0 mM @entity1 , conduction velocity began to decrease in 1-2 minutes and reached a steady state in 15-20 minutes. Conduction velocity in the longitudinal direction decreased from a control value of 0.56 +/- 0.13 to 0.46 +/- 0.10 M/sec (+/- SD) at 30 minutes after @entity1 (p = 0.005). In the transverse direction, it decreased from 0.24 +/- 0.09 to 0.17 +/- 0.05 M/sec (p = 0.002). The ratio of longitudinal to transverse conduction velocities increased from 2.54 +/- 1.00 to 2.94 +/- 0.82 (p = 0.042). Thus, @entity1 preferentially slowed conduction in the transverse direction. Because @entity1 did not greatly influence active membrane properties, we used cable equations to calculate the time course of the change in effective junctional resistivity, which rose from 133.2 omega.cm before @entity1 to 312.2 omega.cm 30 minutes after @entity1 administration. We conclude that @entity1 slows conduction velocity by selectively increasing junctional resistivity. The preferential slowing of conduction in the transverse direction is most likely due to the fact that more junctional resistances are encountered per unit distance in the transverse than in the longitudinal direction.

title: Effects of cellular uncoupling on conduction in anisotropic XXXX ventricular myocardium.

answer: @entity0


abstract: The objective of this study was to elucidate the resistive, elastic, and total inspiratory muscle work and mainly the efficiency of the inspiratory muscle work in still standing and in exercising @entity1 . In 180 experiments with nine mongrel @entity1 , respiratory and circulatory functions were recorded at rest and during a 1.5-mph walk on a treadmill belt which was inclined by 9 degrees. Each @entity1 had been trained and surgically prepared before the series of experiments started. An electronic pressure transducer together with a fluid-filled catheter was attached to the ribs at the midthoracic level. Airflow was monitored with a pneumotachygraph attached to a face mask. Aortic flow was monitored with an electromagnetic flow transducer. Catheters in the atria, the ventricles, and the pulmonary and systemic vessels were used to determine hemodynamic parameters and blood gas levels. All recorded and all derived functions were evaluated by a dedicated computer. At rest, resistive inspiratory work (0.98 kg cm) was smaller than elastic work (1.36 kg cm). Elastic work did not change with exercise but resistive work increased to 1.46 kg.cm. The increase of total work from 2.33 kg.cm at rest to 2.79 kg.cm during exercise did not reach significance. Inspiratory power increased with exercise. Estimated diaphragmatic @entity0 consumption increased from 2.23 ml/min at rest to 3.64 ml/min during exercise. It was 1.6 percent of the total @entity0 consumption at rest and 1.7 percent of the total @entity0 consumption during exercise. The estimated efficiency of the work of inspiratory muscles was 15.8 percent at rest and 25.8 percent during exercise. These values did not vary substantially between different animals.

title: Efficiency of work of inspiratory muscles in standing and in exercising XXXX .

answer: @entity1


abstract: UNASSIGNED: Sixteen female piglets (58 d of age, 16.8      0.8  kg body weight [BW]) were assigned to two groups (n  =  8) and received until day 100 of age (50.3      1.2  kg BW) ad libitum either a diet with a standard (diet C) or low (diet L) total @entity2 (P) content (5.38 and 4.23  g/kg, respectively). Diet C was supplemented with mineral P (1.15  g/kg) and did not contain microbial phytase. Diet L did not contain any inorganic P but 750  FTU/kg of microbial phytase. Despite these treatments, both diets were composed with the same ingredients. Body mineralisation of each gilt was assessed by determining the bone mineral content (BMC), area @entity0 ( @entity0 ) by the dual-energy X-ray absorptiometry (DXA) at days 58, 72, 86 and 100 of age. Feeding diet L caused a higher P digestibility (p  =  0.008) measured from days 72 to 86 of age and at 100  days of age a higher BMC and @entity0 (p   <=  0.01). Furthermore, the gilts of group L deposited more minerals in the body than control @entity1 (by 2.4  g/d, p  =  0.008). It was found that @entity0 and BMC were positively correlated with body lean mass and digestible P intake. The results indicated that, even for very young @entity1 , the addition of microbial phytase instead of inorganic P increases the amount of digestible P covering the requirements of piglets for proper bone mineralisation. Furthermore, it was proved that the DXA method can be successfully applied to measure body fat and lean mass contents as well as bone mineralisation of growing @entity1 using the same animals.

title: Bone mineralisation of weaned piglets fed a diet free of inorganic XXXX and supplemented with phytase, as assessed by dual-energy X-ray absorptiometry.

answer: @entity2


abstract: BACKGROUND: Fast and accurate @entity4 risk stratification in the @entity2 ( @entity2 ) is critical. The HEART score predicts the short-term incidence of major adverse @entity1 (MACE) in this population, dividing it in three risk categories. We aimed to describe the population with @entity4 , to characterize the subgroup of @entity0 with @entity6 ( @entity6 ) and to assess the prognostic value of Manchester triage system and of HEART score. METHODS: Retrospective observational study including @entity0 admitted to the @entity2 of a tertiary hospital with @entity4 as the presenting symptom. The primary outcome was a composite of all-cause mortality, @entity3 or unscheduled revascularization at 6  weeks. RESULTS: We enrolled 233 @entity0 (age 58        19; 55.4  % males). The most common final diagnosis was non-specific @entity4 (n   =   86, 36.9  %), followed by @entity6 (n   =   22, 9.4  %). Male gender, smoking and @entity5 were associated with higher risk of @entity6 . According to Manchester triage system, @entity4 @entity0 stratified with red or orange priority had a higher incidence of @entity6 (16.5  % vs. 3.8  %, p   =   0.006). The application of HEART score showed that most @entity0 were in low risk category (56.3  %). The six-week incidence of MACE in each category was 2  %, 15.6  % and 76.9  % (p   <   0.001). HEART score accurately predicted the short-term incidence of MACE in @entity4 @entity0 (c-statistic 0.880; 95  % CI, 0.807-0.950, p   <   0.001). CONCLUSIONS: @entity4 @entity0 have very different levels of severity and the discriminatory power of Manchester triage system should be used in the assessment of this population. The HEART score seems to be an effective tool for risk stratification in the @entity2 .

title: @entity4 in the XXXX : risk stratification with Manchester triage system and HEART score.

answer: @entity2


abstract: BACKGROUND: Fast and accurate @entity4 risk stratification in the @entity2 ( @entity2 ) is critical. The HEART score predicts the short-term incidence of major adverse @entity1 (MACE) in this population, dividing it in three risk categories. We aimed to describe the population with @entity4 , to characterize the subgroup of @entity0 with @entity6 ( @entity6 ) and to assess the prognostic value of Manchester triage system and of HEART score. METHODS: Retrospective observational study including @entity0 admitted to the @entity2 of a tertiary hospital with @entity4 as the presenting symptom. The primary outcome was a composite of all-cause mortality, @entity3 or unscheduled revascularization at 6  weeks. RESULTS: We enrolled 233 @entity0 (age 58        19; 55.4  % males). The most common final diagnosis was non-specific @entity4 (n   =   86, 36.9  %), followed by @entity6 (n   =   22, 9.4  %). Male gender, smoking and @entity5 were associated with higher risk of @entity6 . According to Manchester triage system, @entity4 @entity0 stratified with red or orange priority had a higher incidence of @entity6 (16.5  % vs. 3.8  %, p   =   0.006). The application of HEART score showed that most @entity0 were in low risk category (56.3  %). The six-week incidence of MACE in each category was 2  %, 15.6  % and 76.9  % (p   <   0.001). HEART score accurately predicted the short-term incidence of MACE in @entity4 @entity0 (c-statistic 0.880; 95  % CI, 0.807-0.950, p   <   0.001). CONCLUSIONS: @entity4 @entity0 have very different levels of severity and the discriminatory power of Manchester triage system should be used in the assessment of this population. The HEART score seems to be an effective tool for risk stratification in the @entity2 .

title: XXXX in the @entity2 : risk stratification with Manchester triage system and HEART score.

answer: @entity4


abstract: BACKGROUND: MicroRNAs (miRNAs) are small noncoding RNAs that act as post-transcriptional regulators of gene targets. Accurate quantification of miRNA expression using validated internal controls should aid in the understanding of their role in epigenetic modification of genome function. To date, most studies that have examined miRNA expression levels have used the global mean expression of all expressed genes or the expression of reference mRNAs or nuclear RNAs for normalization. RESULTS: We analyzed the suitability of a number of miRNAs as potential expression normalizers in @entity0 oocytes and early embryos, and porcine oocytes. The stages examined were @entity0 oocytes at the germinal vesicle (GV) and metaphase II stages, @entity0 zygotes, 2, 4 and 8 cell embryos, morulae and blastocysts, as well as porcine cumulus oocyte complexes, GV, metaphase I and II oocytes. qRT-PCR was performed to quantify expression of @entity4 , miR-103, miR-26a, @entity2 , @entity5 , Let-7a and U6 for @entity0 samples and @entity1 , miR-26a, @entity4 , miR-103, @entity3 , @entity6 and @entity2 for porcine oocytes. The average starting material for each sample was determined using specific standard curves for each primer set. Subsequently, geNorm and BestKeeper software were used to identify a set of stably expressed miRNAs. Stepwise removal to determine the optimum number of reference miRNAs identified @entity4 and miR-103 as the most stably expressed in @entity0 samples and miR-26a, @entity2 and @entity4 in porcine samples. CONCLUSIONS: The combination of @entity4 and miR-103 is optimal for normalizing miRNA expression for qPCR experiments on @entity0 oocytes and preimplantation embryos; the preferred combination for porcine oocytes is miR-26a, @entity2 and @entity4 .

title: Validating reference microRNAs for normalizing qRT-PCR data in XXXX oocytes and preimplantation embryos.

answer: @entity0


abstract: A 50-year-old @entity0 presented with @entity6 , @entity5 , and @entity10 in June 2013. She was diagnosed with de novo @entity15 with the t(16;21)(q24;q22) translocation. She received an allogeneic hematopoietic stem cell transplant from an @entity12 locus-mismatched unrelated donor in June 2014. The myeloablative preparative regimen consisted of @entity9 at 60 mg/kg for 2 days and total body irradiation at 12 Gy. On Day 55, she was treated with @entity8 at 20 mg/day for acute GVHD (Grade III; Skin Stage 2, Gut Stage 2, Liver Stage 0) and gradually improved. She had @entity2 , @entity11 in the upper limbs, and asymptomatic @entity18 on Day 145. Laboratory tests showed elevated CK, CKMB, aldolase, and troponin I. Electromyographic examination revealed @entity1 compatible with the diagnosis of @entity16 . Electrocardiography showed @entity7 and anteroseptal ST elevation, and echocardiography showed @entity14 of the left interventricular septal wall without evidence of @entity3 or @entity13 relapse. She was immediately treated with 40 mg/day @entity8 after the diagnosis of @entity17 and @entity4 , associated with chronic GVHD. The @entity17 and @entity4 improved promptly after the administration of @entity8 and the @entity0 remains in remission with a current maintenance program of @entity8 at 5 mg/day.

title: Chronic GVHD complicated with @entity17 and XXXX after myeloablative hematopoietic stem cell transplantation.

answer: @entity4


abstract: A 50-year-old @entity0 presented with @entity6 , @entity5 , and @entity10 in June 2013. She was diagnosed with de novo @entity15 with the t(16;21)(q24;q22) translocation. She received an allogeneic hematopoietic stem cell transplant from an @entity12 locus-mismatched unrelated donor in June 2014. The myeloablative preparative regimen consisted of @entity9 at 60 mg/kg for 2 days and total body irradiation at 12 Gy. On Day 55, she was treated with @entity8 at 20 mg/day for acute GVHD (Grade III; Skin Stage 2, Gut Stage 2, Liver Stage 0) and gradually improved. She had @entity2 , @entity11 in the upper limbs, and asymptomatic @entity18 on Day 145. Laboratory tests showed elevated CK, CKMB, aldolase, and troponin I. Electromyographic examination revealed @entity1 compatible with the diagnosis of @entity16 . Electrocardiography showed @entity7 and anteroseptal ST elevation, and echocardiography showed @entity14 of the left interventricular septal wall without evidence of @entity3 or @entity13 relapse. She was immediately treated with 40 mg/day @entity8 after the diagnosis of @entity17 and @entity4 , associated with chronic GVHD. The @entity17 and @entity4 improved promptly after the administration of @entity8 and the @entity0 remains in remission with a current maintenance program of @entity8 at 5 mg/day.

title: Chronic GVHD complicated with XXXX and @entity4 after myeloablative hematopoietic stem cell transplantation.

answer: @entity17


abstract: OBJECTIVES: Matrix metalloproteinases (MMPs) has been implicated in the pathogenesis of infective, @entity1 and @entity2 . In this study, we investigated the serum level of MMPs and its clinical importance in @entity0 @entity5 . @entity0 AND METHODS: This study included 60 @entity5 @entity0 treated at the Clinic for Infectious Diseases, Clinical Centre, University of Sarajevo. Matrix metalloproteinases serum levels were quantified by ELISA. RESULTS: The investigation involved three groups: 30 @entity0 with complications, 30 @entity0 without complications of @entity5 and 30 healthy control examinees. The complications of @entity0 @entity5 varied but osteoarticular involvement dominated (n=21/30; 70%). Matrix metalloproteinases serum levels in the @entity0 with complications were highest. The serum level of @entity4 in @entity0 with complications was the highest at 9.45; in @entity0 without complications it was 3.78 and in the control examinees it was lowest at 3.62 (p=0.001). The serum level of @entity3 in @entity0 with complications was the highest at 105.66; in @entity0 without complications 64.67, and in the control examinees it was lowest at 37.32 (p=0.001). The serum level of MMP-13 in @entity0 with complications was highest at 138.86; in @entity0 without complications at 64.85; and in the control examinees it was the lowest at 29.55 (p=0.001). Pearson's coefficient showed a statistically significant positive correlation between levels of tested matrix metalloproteinases and development complications in @entity0 @entity5 (p=0.001). CONCLUSION: This study showed the diagnostic value and importance of detection of matrix metalloproteinases in @entity0 @entity5 . MMPs are a useful serum biomarker for assessment of disease activity.

title: Osteoarticular complications of XXXX : The diagnostic value and importance of detection matrix metalloproteinases.

answer: @entity5


abstract: BACKGROUND: Because large, prospective, population-based data sets describing maternal outcomes are typically not available in low- and middle-income countries, it is difficult to monitor maternal mortality rates over time and to identify factors associated with maternal mortality. Early identification of risk factors is essential to develop comprehensive intervention strategies preventing @entity4 . Our objective was to describe maternal mortality rates in a large, multi-country dataset and to determine maternal, pregnancy-related, delivery and postpartum characteristics that are associated with maternal mortality. METHODS: We collected data describing all pregnancies from 2010 to 2013 among @entity0 enrolled in the multi-national Global Network for @entity0 's and @entity0 's Health Research Maternal and Neonatal Health Registry (MNHR). We reported the proportion of mothers who died per pregnancy and the maternal mortality ratio (MMR). Generalized linear models were used to evaluate the relationship of potential medical and social factors and maternal mortality and to develop point and interval estimates of relative risk associated with these factors. Generalized estimating equations were used to account for the correlation of outcomes within cluster to develop appropriate confidence intervals. RESULTS: We recorded 277,736 pregnancies and 402 maternal deaths for an MMR of 153/100,000 live births. We observed an improvement in the total MMR from 166 in 2010 to 126 in 2013. The MMR in Latin American sites (91) was lower than the MMR in Asian (178) and African sites (125). When adjusted for study site and the other variables, no formal education (RR 3.2 [1.5, 6.9]), primary education only (RR 3.4 [1.6, 7.5]), secondary education only (RR 2.5 [1.1, 5.7]), lack of antenatal care (RR 1.8 [1.2, 2.5]), caesarean section delivery (RR 1.9 [1.3, 2.8]), @entity3 (RR 3.3 [2.2, 5.1]), and @entity1 (RR 7.4 [5.2, 10.4]) were associated with higher risks of @entity2 . CONCLUSIONS: The MNHR identified preventable causes of maternal mortality in diverse settings in low- and middle-income countries. The MNHR can be used to monitor public health strategies and determine their association with reducing maternal mortality. TRIAL REGISTRATION: clinicaltrials.gov NCT01073475.

title: Risk factors for XXXX and trends in maternal mortality in low- and middle-income countries: a prospective longitudinal cohort analysis.

answer: @entity2


abstract: PURPOSE: There are very few reported cases of @entity3 following spinal surgery via a posterior approach. An association between @entity3 and muscle over-activity via nerve stimulation during evoked potential monitoring was first suggested in 2003. No further reports have suggested this link. We present a multicentre retrospective review of a series of five @entity0 who developed @entity3 following spinal surgery via a posterior approach, whilst un-paralysed and with combined sensory (SSEP)/motor evoked potential (MEP) monitoring with an aim of highlighting this possible causative factor. METHODS: All data were collected contemporaneously and retrospective analysis was performed. We then arranged for a multidisciplinary review of the cases including surgeons, anaesthetists, radiologists, neurophysiologists and theatre and ward nursing staff. Finally, the literature was reviewed. RESULTS: All @entity0 were operated on by three different surgeons, on different operating tables/mattresses in the prone position. The common factors were un-paralysed @entity0 having motor/sensory monitoring, mechanical @entity2 pumps and total intravenous anaesthesia. Three @entity0 underwent surgical decompression of their compartments and two were treated expectantly. Three @entity0 had confirmed intra-compartmental changes on MRI consistent with @entity3 and one had intra-compartmental pressure monitoring which confirmed the diagnosis. CONCLUSIONS: Previous cases in the literature have related to mal-positioning on the Jackson table or use of the knee-chest position for surgery. This was not the case for our @entity0 ; therefore, we suspect an association between overactive muscle stimulation and @entity1 . Further experimental studies investigating this link are required.

title: A multicentre retrospective review of XXXX of the leg following spinal surgery with motor evoked potential monitoring: a cause for concern?

answer: @entity1


abstract: Skinned fibers from striated muscle were used to study the intracellular mechanisms (contractile proteins and sarcoplasmic reticulum [SR]) of action of @entity6 (DT) and @entity4 (VP) on muscle contraction. @entity0 papillary muscle (PM), and the skeletal muscles adductor magnus (AM, fast-twitch) and soleus (SL, slow-twitch) were used. The muscles were skinned by homogenization and fibre bundles for PM and single fibres for AM and SL were dissected from the homogenate and mounted on photodiode force transducers. VP (0.1-3.0 mmol/l) (and to a lesser degree DT) increased @entity1 -activated @entity5 development of the contractile protains in PM and SL and decreased it in AM (+[4-20]%, +4%, -[14-28]%, respectively). Both drugs increased the submaximal @entity1 -activated @entity5 development at the order of PM = SL greater than AM in a dose-dependent manner. The changes of half-maximal pCa50 at 1 mmol/l VP were 0.25, 0.25, and 0.15, respectively. For @entity1 uptake and release from the SR, VP as well as DT (0.1-3.0 mmol/l) in the uptake phase decreased @entity7 -induced @entity5 transients in a dose-dependent fashion. At 0.01-3.0 mmol/l, the drugs directly induced @entity1 release from the SR or enhanced @entity7 -induced @entity5 transients with the exception that in PM, DT attenuated @entity7 -induced @entity5 transients. Thus, VP and DT have similar intracellular mechanisms of action in striated muscle. Both drugs induced @entity2 release from the SR and increase @entity1 sensitivity of the contractile proteins, and thus could be the underlying mechanisms for potentiating twitch @entity5 , and inducing @entity3 .

title: Intracellular mechanisms of XXXX and @entity6 action on striated muscle of the @entity0 .

answer: @entity4


abstract: Skinned fibers from striated muscle were used to study the intracellular mechanisms (contractile proteins and sarcoplasmic reticulum [SR]) of action of @entity6 (DT) and @entity4 (VP) on muscle contraction. @entity0 papillary muscle (PM), and the skeletal muscles adductor magnus (AM, fast-twitch) and soleus (SL, slow-twitch) were used. The muscles were skinned by homogenization and fibre bundles for PM and single fibres for AM and SL were dissected from the homogenate and mounted on photodiode force transducers. VP (0.1-3.0 mmol/l) (and to a lesser degree DT) increased @entity1 -activated @entity5 development of the contractile protains in PM and SL and decreased it in AM (+[4-20]%, +4%, -[14-28]%, respectively). Both drugs increased the submaximal @entity1 -activated @entity5 development at the order of PM = SL greater than AM in a dose-dependent manner. The changes of half-maximal pCa50 at 1 mmol/l VP were 0.25, 0.25, and 0.15, respectively. For @entity1 uptake and release from the SR, VP as well as DT (0.1-3.0 mmol/l) in the uptake phase decreased @entity7 -induced @entity5 transients in a dose-dependent fashion. At 0.01-3.0 mmol/l, the drugs directly induced @entity1 release from the SR or enhanced @entity7 -induced @entity5 transients with the exception that in PM, DT attenuated @entity7 -induced @entity5 transients. Thus, VP and DT have similar intracellular mechanisms of action in striated muscle. Both drugs induced @entity2 release from the SR and increase @entity1 sensitivity of the contractile proteins, and thus could be the underlying mechanisms for potentiating twitch @entity5 , and inducing @entity3 .

title: Intracellular mechanisms of @entity4 and XXXX action on striated muscle of the @entity0 .

answer: @entity6


abstract: Skinned fibers from striated muscle were used to study the intracellular mechanisms (contractile proteins and sarcoplasmic reticulum [SR]) of action of @entity6 (DT) and @entity4 (VP) on muscle contraction. @entity0 papillary muscle (PM), and the skeletal muscles adductor magnus (AM, fast-twitch) and soleus (SL, slow-twitch) were used. The muscles were skinned by homogenization and fibre bundles for PM and single fibres for AM and SL were dissected from the homogenate and mounted on photodiode force transducers. VP (0.1-3.0 mmol/l) (and to a lesser degree DT) increased @entity1 -activated @entity5 development of the contractile protains in PM and SL and decreased it in AM (+[4-20]%, +4%, -[14-28]%, respectively). Both drugs increased the submaximal @entity1 -activated @entity5 development at the order of PM = SL greater than AM in a dose-dependent manner. The changes of half-maximal pCa50 at 1 mmol/l VP were 0.25, 0.25, and 0.15, respectively. For @entity1 uptake and release from the SR, VP as well as DT (0.1-3.0 mmol/l) in the uptake phase decreased @entity7 -induced @entity5 transients in a dose-dependent fashion. At 0.01-3.0 mmol/l, the drugs directly induced @entity1 release from the SR or enhanced @entity7 -induced @entity5 transients with the exception that in PM, DT attenuated @entity7 -induced @entity5 transients. Thus, VP and DT have similar intracellular mechanisms of action in striated muscle. Both drugs induced @entity2 release from the SR and increase @entity1 sensitivity of the contractile proteins, and thus could be the underlying mechanisms for potentiating twitch @entity5 , and inducing @entity3 .

title: Intracellular mechanisms of @entity4 and @entity6 action on striated muscle of the XXXX .

answer: @entity0


abstract: UNASSIGNED: We used samples from @entity1 ( @entity1 ) @entity0 to examine whether Anti-citrullinated protein antibodies (ACPAs) alter macrophage subset distribution and promote @entity1 development. Macrophage subset distributions and @entity4 ( @entity4 ) and @entity5 expressions were analyzed. ACPAs were purified by affinity column. After @entity1 and @entity2 ( @entity2 ) @entity0 ' macrophages were cocultured with ACPAs, macrophage subsets and @entity4 and @entity5 expressions were measured. Small interfering RNAs (siRNAs) were transfected into @entity3 -activated cells to suppress @entity4 or @entity5 . Fluorescence-activated cell sorting (FACS), Western blot, and immunohistochemistry were performed. Macrophage subset disequilibrium occurred in @entity1 @entity0 synovial fluids. @entity4 and @entity5 were all expressed in the synovial fluid and synovium. ACPAs (40  IU/ml) could induce macrophages to polarize to M1 subsets, and the percentage of increased M1/M2 ratio of @entity1 @entity0 was higher than that of the @entity2 @entity0 . ACPAs also induce @entity4 and @entity5 protein expressions. @entity5 siRNA transfection impaired @entity3 activity significantly. We demonstrated that macrophage subset disequilibrium occurred in @entity1 @entity0 . ACPAs induced @entity5 activity and led to M1 macrophage polarization.

title: Anti-Citrullinated Protein Antibodies Induce Macrophage Subset Disequilibrium in XXXX @entity0 .

answer: @entity1


abstract: UNASSIGNED: We used samples from @entity1 ( @entity1 ) @entity0 to examine whether Anti-citrullinated protein antibodies (ACPAs) alter macrophage subset distribution and promote @entity1 development. Macrophage subset distributions and @entity4 ( @entity4 ) and @entity5 expressions were analyzed. ACPAs were purified by affinity column. After @entity1 and @entity2 ( @entity2 ) @entity0 ' macrophages were cocultured with ACPAs, macrophage subsets and @entity4 and @entity5 expressions were measured. Small interfering RNAs (siRNAs) were transfected into @entity3 -activated cells to suppress @entity4 or @entity5 . Fluorescence-activated cell sorting (FACS), Western blot, and immunohistochemistry were performed. Macrophage subset disequilibrium occurred in @entity1 @entity0 synovial fluids. @entity4 and @entity5 were all expressed in the synovial fluid and synovium. ACPAs (40  IU/ml) could induce macrophages to polarize to M1 subsets, and the percentage of increased M1/M2 ratio of @entity1 @entity0 was higher than that of the @entity2 @entity0 . ACPAs also induce @entity4 and @entity5 protein expressions. @entity5 siRNA transfection impaired @entity3 activity significantly. We demonstrated that macrophage subset disequilibrium occurred in @entity1 @entity0 . ACPAs induced @entity5 activity and led to M1 macrophage polarization.

title: Anti-Citrullinated Protein Antibodies Induce Macrophage Subset Disequilibrium in @entity1 XXXX .

answer: @entity0


abstract: UNASSIGNED: @entity3 has been the second most important determinant of disease burden in Iran since the 1990s. Despite well-recognized evidence on the association of high blood pressure and mortality in other countries, this relationship has not been fully investigated in the demographic setting of Iran. The current study is the first large-scale longitudinal study of this association in Iran. Briefly, 50   045 subjects between 40 and 75 years of age have been recruited and followed. Blood pressure measurements were carried out at baseline. Causes of @entity4 were reported and verified by verbal autopsy throughout the follow-up period. The outcomes of interest were all-cause @entity4 and @entity4 due to @entity5 ( @entity5 ) or @entity1 . Cox proportional hazards regression models were used to estimate hazard ratios (HRs). A total of 46 674 subjects free from @entity2 at baseline were analyzed. Absolute mortality rates increased along with increasing systolic or diastolic blood pressure above 120 and 80   mm   Hg, respectively. Adjusted HRs (95% confidence intervals) for each 20   mm   Hg increase in systolic blood pressure in all age groups were 1.18 (1.13-1.23) for all-cause mortality, 1.21 (1.13-1.31) for @entity4 due to @entity5 and 1.50 (1.39-1.63) for @entity4 due to @entity1 . Unadjusted and adjusted HRs were higher in younger subjects and decreased with increasing age of the @entity0 . @entity3 is a serious threat to the health of Iranians. The entire health-care system of Iran should be involved in a comprehensive action plan for controlling blood pressure.Journal of @entity0 @entity3 advance online publication, 11 June 2015; doi:10.1038/jhh.2015.57.

title: XXXX and mortality in the Golestan Cohort Study: A prospective study of 50   000 adults in Iran.

answer: @entity3


abstract: OBJECTIVE: To compare the video-assisted thoracoscopic surgery (VATS) with the open thoracotomy access to @entity3 by the clinical outcomes and long-term survival in @entity1 . METHODS: Non-randomized comparative intention-to-treat study of prospective institutional registry data and survival data of 100 consecutive @entity0 undergoing segmentectomy. RESULTS: Within one decade (2002-12), 100 @entity0 with proven or highly suspected @entity1 underwent 100 anatomical sub-lobar pulmonary resections (52 typical and 20 atypical segmentectomies, 28 split-lobe procedures). Fifty-six @entity0 were operated by VATS and 44 by thoracotomy access. Comparison of demographic, medical, oncological and surgical baseline data did not provide evidence for differences between the VATS and thoracotomy groups. The surgery time for the VATS group was 225    62 min and 195    57 min for the thoracotomy group (P = 0.014). Postoperative hospitalization was 9 days for the VATS group and 12 days for the thoracotomy group (P = 0.034). Postoperative morbidity was 35.7% for the VATS group and 50% for the thoracotomy group (P = 0.161). Both groups had no 30-day mortality. Conversion to thoracotomy occurred in 30.4% of the VATS group. Conversion was more frequent in @entity0 with male gender, critical and prohibitive lung function, @entity2 with diameters exceeding 3 cm and atypical segmentectomies. The fractions of the pathological Union international contre le @entity2 (UICC) stages I, II and III were 74.4, 11.6 and 14% in the VATS group, and 70, 20 and 10% in the thoracotomy group (P = 0.445), respectively. Five-year overall survival was 86% in the VATS group and 69.9% in the thoracotomy group (P = 0.047), and 5-year recurrence-free survival was 58.5 and 48.6% (P = 0.480), respectively. CONCLUSIONS: Compared with thoracotomy access, the VATS approach to segmentectomy was associated with less postoperative morbidity and a 25% decrease in median hospital stay, despite a conversion rate of 30% due to the inclusion of atypical segmentectomies, higher @entity2 stages and @entity0 with critical function for single lung ventilation. Five-year survival estimates suggested a small but significant overall survival benefit and a 10% difference of recurrence-free survival in favour of VATS. Although not fully conclusive, long-term results indicate that the thoracoscopic access to segmentectomy is probably not inferior to the thoracotomy approach. Confirmation by a larger number of risk-adjusted outcome data is required.

title: Comparative intention-to-treat analysis of the video-assisted thoracoscopic surgery approach to XXXX   .

answer: @entity1


abstract: UNASSIGNED: Botulinum toxin is a widely used treatment with satisfactory results, and it is relatively safe in the doses used for cosmetic procedures. The authors report a case of @entity1 to Chinese botulinum toxin serotype A (CBTX-A). Although this is a rare adverse event, it is nonetheless clinically relevant to healthcare professionals. A 44-year-old @entity0 presented to the authors' hospital complaining of dynamic wrinkles. CBTX-A was used to treat her. Minutes after application, she developed urticarial plaques proximal to the injection site. The @entity0 had an @entity1 , as documented by a positive skin test, which was controlled by the administration of antihistamines and systemic @entity2 . This report is intended to guide healthcare professionals faced with this type of adverse event regarding how to proceed without hindering the delivery and effectiveness of the treatment. When performed by a qualified health professional, this treatment brings excellent results in the vast majority of cases. LEVEL OF EVIDENCE: 5 Risk.

title: Report of XXXX After Application of Botulinum Toxin.

answer: @entity1


abstract: The persistence of collateral circulation was evaluated one year after the correction of experimental @entity1 ( @entity2 ) by assessing renal perfusion with the Xenon 133-washout method and measuring distal aortic blood pressure during cross-clamping of the thoracic aorta. @entity2 was created in 7 puppies at 2 months of age and was corrected after a follow-up with a venous patch when the @entity0 were 9 months old. Two of the @entity0 were lost during the corrective operation due to anaesthetic complications. Four sham-operated @entity0 served as controls. One year after correction of @entity2 , four of the @entity0 had a pressure gradient of less than 5 mmHg at the site of @entity2 and one a pressure gradient of 15 mmHg. In renal perfusion measurements a mean decrease of 49% and 96% was found in the study and control groups, respectively. Blood pressures in the distal aorta decreased 47% and 83%, respectively. Two @entity0 in the study group had a distal blood pressure under 50 mmHg and their renal perfusion decreased markedly. Collateral circulation decreased with time after a good anatomic correction of @entity2 , so that one year after correction of experimental @entity2 about one half of the initial collateral capacity remained. This suggests that in most reoperations performed at least one year after the primary corrections, temporal shunting or a left side bypass is necessary to ensure sufficient circulation in the distal organs.

title: Persistence of collateral circulation after correction of XXXX .

answer: @entity1


abstract: BACKGROUND: @entity4 ( @entity4 ) shares several similarities with @entity6 . Recent reports showed that B cells are implicated in @entity6 progression through macrophage-B cells bidirectional interaction. We aimed to study the in loco presence of B cells within aortic valves and to determine its modulators. METHODS: Thirty-seven @entity0 with severe @entity4 were studied. Immunohistochemistry was performed on valve leaflets using antibodies against @entity7 , B cell-activating factor of the @entity1 necrosis factor family receptor ( @entity8 ) and @entity3 . Plasma inflammatory markers were also determined. RESULTS: The B cells were detected within aortic leaflets from 5 to 31/mm(2) (17.9  11.6/mm(2)). Double-staining showed that 27  13.5% of B cells express @entity8 . There were positive correlations between the number of B cells and macrophages (r=0.45, p=0.018), and between macrophages and B cell-associated @entity8 expression (r=0.66, p=0.002). The number of B cells was associated with the valve @entity5 (r=0.41, p=0.039), and with the maximum transvalvular gradient (r=0.63, p=0.02). The @entity8 expression was positively correlated with maximum transvalvular gradient (r=0.39, p=0.031) and negatively with aortic valve area (r=-0.41, p=0.048). There were no correlations between the number of B cells and plasma markers. CONCLUSIONS: It might be hypothesized that, like in @entity6 , increasing number of B cells within aortic valves may accelerate @entity2 and thus potentiate the progression of @entity4 .

title: Presence of B cells within aortic valves in @entity0 with XXXX : Relation to severity of the disease.

answer: @entity4


abstract: BACKGROUND: @entity4 ( @entity4 ) shares several similarities with @entity6 . Recent reports showed that B cells are implicated in @entity6 progression through macrophage-B cells bidirectional interaction. We aimed to study the in loco presence of B cells within aortic valves and to determine its modulators. METHODS: Thirty-seven @entity0 with severe @entity4 were studied. Immunohistochemistry was performed on valve leaflets using antibodies against @entity7 , B cell-activating factor of the @entity1 necrosis factor family receptor ( @entity8 ) and @entity3 . Plasma inflammatory markers were also determined. RESULTS: The B cells were detected within aortic leaflets from 5 to 31/mm(2) (17.9  11.6/mm(2)). Double-staining showed that 27  13.5% of B cells express @entity8 . There were positive correlations between the number of B cells and macrophages (r=0.45, p=0.018), and between macrophages and B cell-associated @entity8 expression (r=0.66, p=0.002). The number of B cells was associated with the valve @entity5 (r=0.41, p=0.039), and with the maximum transvalvular gradient (r=0.63, p=0.02). The @entity8 expression was positively correlated with maximum transvalvular gradient (r=0.39, p=0.031) and negatively with aortic valve area (r=-0.41, p=0.048). There were no correlations between the number of B cells and plasma markers. CONCLUSIONS: It might be hypothesized that, like in @entity6 , increasing number of B cells within aortic valves may accelerate @entity2 and thus potentiate the progression of @entity4 .

title: Presence of B cells within aortic valves in XXXX with @entity4 : Relation to severity of the disease.

answer: @entity0


abstract: BACKGROUND: It is important to identify @entity1 in @entity0 at high risk. To include genetics into routine cardiological @entity0 has therefore been discussed recently. We wanted to evaluate the association between high-molecular weight @entity2 and cardiovascular risk, and secondly in the same population evaluate if specific genotype differences regarding risk could be observed, and thirdly if gender differences could be seen. METHOD: Four hundred seventy-six elderly @entity0 recruited from a rural community were included. All @entity0 underwent a clinical examination, echocardiography, and blood sampling and the single nucleotide polymorphism (SNP) ( @entity3 ) of @entity2 was analysed. Follow-up time was 6.7 years. RESULTS: Those with high serum concentration of @entity2 had a more 2 fold increased cardiovascular risk, and it might be that females exhibits even higher risk where a more than 5 fold increased risk could be seen. The result could be demonstrated even in a multivariate model adjusting for well-known clinical risk factors. However, as the sample size was small the gender differences should be interpreted with caution. In the genotype evaluation the C/C carriers of the female group had a more than 9-fold increased risk of @entity1 , however the confidence interval was wide. Such genotype difference could not be found in the male group. CONCLUSION: High level of @entity2 was associated with increased cardiovascular risk. Also a gender difference in the genotype evaluation could be seen where the C/C carriers obtained higher risk in the female group but not in the male group. Thus, in order to identify @entity0 at risk early, genetic analyses may add to the armamentarium used in the clinical routine. However, information should be regarded as hypothesis generating as the sample size was small and should stimulate further research in individualized cardiovascular prevention and treatment.

title: Gender difference in @entity2 associated with XXXX .

answer: @entity1


abstract: BACKGROUND: It is important to identify @entity1 in @entity0 at high risk. To include genetics into routine cardiological @entity0 has therefore been discussed recently. We wanted to evaluate the association between high-molecular weight @entity2 and cardiovascular risk, and secondly in the same population evaluate if specific genotype differences regarding risk could be observed, and thirdly if gender differences could be seen. METHOD: Four hundred seventy-six elderly @entity0 recruited from a rural community were included. All @entity0 underwent a clinical examination, echocardiography, and blood sampling and the single nucleotide polymorphism (SNP) ( @entity3 ) of @entity2 was analysed. Follow-up time was 6.7 years. RESULTS: Those with high serum concentration of @entity2 had a more 2 fold increased cardiovascular risk, and it might be that females exhibits even higher risk where a more than 5 fold increased risk could be seen. The result could be demonstrated even in a multivariate model adjusting for well-known clinical risk factors. However, as the sample size was small the gender differences should be interpreted with caution. In the genotype evaluation the C/C carriers of the female group had a more than 9-fold increased risk of @entity1 , however the confidence interval was wide. Such genotype difference could not be found in the male group. CONCLUSION: High level of @entity2 was associated with increased cardiovascular risk. Also a gender difference in the genotype evaluation could be seen where the C/C carriers obtained higher risk in the female group but not in the male group. Thus, in order to identify @entity0 at risk early, genetic analyses may add to the armamentarium used in the clinical routine. However, information should be regarded as hypothesis generating as the sample size was small and should stimulate further research in individualized cardiovascular prevention and treatment.

title: Gender difference in XXXX associated with @entity1 .

answer: @entity2


abstract: AIMS: To elucidate if topically applied @entity3 safely decreases corneal @entity2 staining in dry eyes associated with @entity4 . METHODS: Ten @entity1 and @entity4 (DEB) @entity0 were enroled in a prospective pilot study. All @entity0 were treated with topical @entity3 (50  M) 8 times a day for 4 weeks and allowed to continue with their existing @entity1 treatment. The @entity0 were examined weekly for 4 weeks. The primary outcome measure was corneal @entity2 staining. Secondary outcome measures were tear film break-up time (BUT), Schirmer I testing, @entity4 score and bulbar conjunctival injection. The subjective efficacy was evaluated with global symptom and facial analogue scores. RESULTS: An improvement in corneal @entity2 staining in the treated eye by >1 point from baseline to completion of the trial at week 4 was found in 9 of 10 @entity0 (p < 0.01). Topical @entity3 significantly improved the tear film BUT (p < 0.01), @entity4 score (p < 0.05) and bulbar conjunctival injection (p < 0.05). The global symptom score and facial analogue score also improved (p < 0.05). There were no side effects. CONCLUSION: Topical @entity3 is a potential therapy for DEB @entity0 . Larger comparative clinical studies are required to establish the efficacy and safety of topical @entity3 .    2015 S. Karger AG, Basel.

title: Efficacy and Safety of Topical @entity3 for the Treatment of Dry Eye Associated with XXXX : A Pilot Study.

answer: @entity4


abstract: AIMS: To elucidate if topically applied @entity3 safely decreases corneal @entity2 staining in dry eyes associated with @entity4 . METHODS: Ten @entity1 and @entity4 (DEB) @entity0 were enroled in a prospective pilot study. All @entity0 were treated with topical @entity3 (50  M) 8 times a day for 4 weeks and allowed to continue with their existing @entity1 treatment. The @entity0 were examined weekly for 4 weeks. The primary outcome measure was corneal @entity2 staining. Secondary outcome measures were tear film break-up time (BUT), Schirmer I testing, @entity4 score and bulbar conjunctival injection. The subjective efficacy was evaluated with global symptom and facial analogue scores. RESULTS: An improvement in corneal @entity2 staining in the treated eye by >1 point from baseline to completion of the trial at week 4 was found in 9 of 10 @entity0 (p < 0.01). Topical @entity3 significantly improved the tear film BUT (p < 0.01), @entity4 score (p < 0.05) and bulbar conjunctival injection (p < 0.05). The global symptom score and facial analogue score also improved (p < 0.05). There were no side effects. CONCLUSION: Topical @entity3 is a potential therapy for DEB @entity0 . Larger comparative clinical studies are required to establish the efficacy and safety of topical @entity3 .    2015 S. Karger AG, Basel.

title: Efficacy and Safety of Topical XXXX for the Treatment of Dry Eye Associated with @entity4 : A Pilot Study.

answer: @entity3


abstract: PURPOSE: By integrating intraoperative near infrared fluorescence imaging into a robotic system, surgeons can identify the vascular anatomy in real-time with the technical advantages of robotics that is useful for meticulous lymphovascular dissection. Herein, we report our initial experience of robotic low ligation of the inferior mesenteric artery (IMA) with real-time identification of the vascular system for @entity1 using the Firefly technique. MATERIALS AND METHODS: The study group included 11 @entity0 who underwent a robotic total mesorectal excision with preservation of the left colic artery for @entity1 using the Firefly technique between July 2013 and December 2013. RESULTS: The procedures included five low anterior resections and six ultra-low anterior resections with loop ileostomy. The median total operation time was 327 min (226-490). The low ligation time was 10 min (6-20), and the time interval between @entity5 injection and division of the sigmoid artery was 5 min (2-8). The estimated @entity2 was 200 mL (100-500). The median time to soft diet was 4 days (4-5), and the median length of stay was 7 days (5-9). Three @entity0 developed @entity3 ; one @entity0 developed @entity4 , one developed ileus, and one developed non-complicated intraabdominal fluid collection. The median total number of lymph nodes harvested was 17 (9-29). CONCLUSION: Robotic low ligation of the IMA with real-time identification of the vascular system for @entity1 using the Firefly technique is safe and feasible. This technique can allow for precise lymph node dissection along the IMA and facilitate the identification of the left colic branch of the IMA.

title: Robotic Low Ligation of the Inferior Mesenteric Artery for XXXX Using the Firefly Technique.

answer: @entity1


abstract: Numerous @entity1 , including colonic, lung, stomach, and prostate, have been found to have increased concentrations of lipid-associated @entity5 ( @entity6 ). CA 19-9 is a @entity4 antigen found on the membrane surface of pancreatic, gastric, and @entity2 . A prospective study involving 25 @entity0 (15 males, 10 females) with @entity3 ( @entity3 ) was undertaken to examine the clinical value of these two markers. @entity0 ' ages ranged from twenty-five to seventy-seven years (mean 56 years). The group consisted of 9 Stage I, 1 Stage II, 5 Stage III, and 10 Stage IV @entity0 . Twenty three of the 25 had known disease present when tested. Eleven @entity0 with no known @entity1 were used as an age-matched control group. Sixteen of the 23 @entity0 with known disease (70%) had elevated LASA values. Nine of the 11 control @entity0 (82%) had normal LASA values. Three of 7 @entity0 with values obtained pre- and post-nephrectomy showed levels returned to normal after nephrectomy; 3 had persistent LASA elevation and were found to have either metastatic or recurrent disease, and 1 had a persistent elevation of his LASA value without known metastatic or recurrent disease. When the 23 @entity0 with known disease were compared according to stage, 62 percent of Stages I and II, 80 percent of Stage III, and 70 percent of Stage IV had elevated LASA values. There was no statistically significant difference between LASA values and @entity1 stage. CA 19-9 values obtained in 15 of 25 @entity0 with @entity3 were within normal range.

title: Significance of lipid-associated @entity5 and CA 19-9 as @entity1 markers for XXXX .

answer: @entity3


abstract: Numerous @entity1 , including colonic, lung, stomach, and prostate, have been found to have increased concentrations of lipid-associated @entity5 ( @entity6 ). CA 19-9 is a @entity4 antigen found on the membrane surface of pancreatic, gastric, and @entity2 . A prospective study involving 25 @entity0 (15 males, 10 females) with @entity3 ( @entity3 ) was undertaken to examine the clinical value of these two markers. @entity0 ' ages ranged from twenty-five to seventy-seven years (mean 56 years). The group consisted of 9 Stage I, 1 Stage II, 5 Stage III, and 10 Stage IV @entity0 . Twenty three of the 25 had known disease present when tested. Eleven @entity0 with no known @entity1 were used as an age-matched control group. Sixteen of the 23 @entity0 with known disease (70%) had elevated LASA values. Nine of the 11 control @entity0 (82%) had normal LASA values. Three of 7 @entity0 with values obtained pre- and post-nephrectomy showed levels returned to normal after nephrectomy; 3 had persistent LASA elevation and were found to have either metastatic or recurrent disease, and 1 had a persistent elevation of his LASA value without known metastatic or recurrent disease. When the 23 @entity0 with known disease were compared according to stage, 62 percent of Stages I and II, 80 percent of Stage III, and 70 percent of Stage IV had elevated LASA values. There was no statistically significant difference between LASA values and @entity1 stage. CA 19-9 values obtained in 15 of 25 @entity0 with @entity3 were within normal range.

title: Significance of lipid-associated @entity5 and CA 19-9 as XXXX markers for @entity3 .

answer: @entity1


abstract: Numerous @entity1 , including colonic, lung, stomach, and prostate, have been found to have increased concentrations of lipid-associated @entity5 ( @entity6 ). CA 19-9 is a @entity4 antigen found on the membrane surface of pancreatic, gastric, and @entity2 . A prospective study involving 25 @entity0 (15 males, 10 females) with @entity3 ( @entity3 ) was undertaken to examine the clinical value of these two markers. @entity0 ' ages ranged from twenty-five to seventy-seven years (mean 56 years). The group consisted of 9 Stage I, 1 Stage II, 5 Stage III, and 10 Stage IV @entity0 . Twenty three of the 25 had known disease present when tested. Eleven @entity0 with no known @entity1 were used as an age-matched control group. Sixteen of the 23 @entity0 with known disease (70%) had elevated LASA values. Nine of the 11 control @entity0 (82%) had normal LASA values. Three of 7 @entity0 with values obtained pre- and post-nephrectomy showed levels returned to normal after nephrectomy; 3 had persistent LASA elevation and were found to have either metastatic or recurrent disease, and 1 had a persistent elevation of his LASA value without known metastatic or recurrent disease. When the 23 @entity0 with known disease were compared according to stage, 62 percent of Stages I and II, 80 percent of Stage III, and 70 percent of Stage IV had elevated LASA values. There was no statistically significant difference between LASA values and @entity1 stage. CA 19-9 values obtained in 15 of 25 @entity0 with @entity3 were within normal range.

title: Significance of lipid-associated XXXX and CA 19-9 as @entity1 markers for @entity3 .

answer: @entity5